Contrasting DarioHealth (NASDAQ:DRIO) and Avinger (NASDAQ:AVGR)

Avinger (NASDAQ:AVGRGet Free Report) and DarioHealth (NASDAQ:DRIOGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Avinger and DarioHealth’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avinger -239.41% N/A -106.16%
DarioHealth -165.96% -46.38% -30.55%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Avinger and DarioHealth, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avinger 0 0 1 0 3.00
DarioHealth 0 0 2 0 3.00

Avinger presently has a consensus price target of $5.00, indicating a potential upside of 61.81%. DarioHealth has a consensus price target of $5.37, indicating a potential upside of 303.51%. Given DarioHealth’s higher probable upside, analysts plainly believe DarioHealth is more favorable than Avinger.

Insider and Institutional Ownership

18.3% of Avinger shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 4.3% of Avinger shares are owned by company insiders. Comparatively, 10.1% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Avinger and DarioHealth’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avinger $7.65 million 0.69 -$18.32 million ($26.34) -0.12
DarioHealth $20.35 million 1.78 -$59.43 million ($1.03) -1.29

Avinger has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Avinger has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.

Summary

DarioHealth beats Avinger on 10 of the 13 factors compared between the two stocks.

About Avinger

(Get Free Report)

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.

About DarioHealth

(Get Free Report)

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.